160 related articles for article (PubMed ID: 10594779)
1. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis.
Hirata M; Katsumata K; Masaki T; Koike N; Endo K; Tsunemi K; Ohkawa H; Kurokawa K; Fukagawa M
Kidney Int; 1999 Dec; 56(6):2040-7. PubMed ID: 10594779
[TBL] [Abstract][Full Text] [Related]
2. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
3. Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism.
Shiizaki K; Hatamura I; Negi S; Sakaguchi T; Saji F; Kunimoto K; Okamoto M; Imazeki I; Muragaki Y; Akizawa T
Kidney Int; 2006 Aug; 70(3):486-95. PubMed ID: 16788697
[TBL] [Abstract][Full Text] [Related]
4. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. NPS R-568 halts or reverses osteitis fibrosa in uremic rats.
Wada M; Ishii H; Furuya Y; Fox J; Nemeth EF; Nagano N
Kidney Int; 1998 Feb; 53(2):448-53. PubMed ID: 9461105
[TBL] [Abstract][Full Text] [Related]
7. Zinc nutritional status modifies renal osteodystrophy in uremic rats.
Kimmel PL; Langman CB; Bognar B; Faugere MC; Chawla LS; Watkins DW; Malluche HH
Clin Nephrol; 2001 Dec; 56(6):445-58. PubMed ID: 11770796
[TBL] [Abstract][Full Text] [Related]
8. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism.
Tsukamoto Y; Hanaoka M; Matsuo T; Saruta T; Nomura M; Takahashi Y
Am J Kidney Dis; 2000 Mar; 35(3):458-64. PubMed ID: 10692271
[TBL] [Abstract][Full Text] [Related]
9. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7.
González EA; Lund RJ; Martin KJ; McCartney JE; Tondravi MM; Sampath TK; Hruska KA
Kidney Int; 2002 Apr; 61(4):1322-31. PubMed ID: 11918739
[TBL] [Abstract][Full Text] [Related]
10. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB
Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
[TBL] [Abstract][Full Text] [Related]
11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
12. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia.
Tamagaki K; Yuan Q; Ohkawa H; Imazeki I; Moriguchi Y; Imai N; Sasaki S; Takeda K; Fukagawa M
Nephrol Dial Transplant; 2006 Mar; 21(3):651-9. PubMed ID: 16311258
[TBL] [Abstract][Full Text] [Related]
13. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
Brown AJ; Ritter CR; Finch JL; Morrissey J; Martin KJ; Murayama E; Nishii Y; Slatopolsky E
J Clin Invest; 1989 Sep; 84(3):728-32. PubMed ID: 2760211
[TBL] [Abstract][Full Text] [Related]
14. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
15. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3.
Hirata M; Katsumata K; Endo K; Fukushima N; Ohkawa H; Fukagawa M
Nephrol Dial Transplant; 2003 Sep; 18(9):1770-6. PubMed ID: 12937223
[TBL] [Abstract][Full Text] [Related]
16. [Maxacalcitol, a medicine for secondary hyperparathyroidism (2 degrees HPT)].
Imazeki I
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):65-72. PubMed ID: 12617040
[TBL] [Abstract][Full Text] [Related]
17. Hyperphosphatemia modestly retards parathyroid hormone suppression during calcitriol-induced hypercalcemia in normal and azotemic rats.
Jara A; Chacón C; Felsenfeld AJ
Nephron; 2002 Dec; 92(4):883-8. PubMed ID: 12399635
[TBL] [Abstract][Full Text] [Related]
18. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
Morio K; Koide K
Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
[TBL] [Abstract][Full Text] [Related]
19. Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease.
Malluche HH; Monier-Faugere MC; Koszewski NJ
Nephrol Dial Transplant; 2002; 17 Suppl 10():6-9. PubMed ID: 12386263
[TBL] [Abstract][Full Text] [Related]
20. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.
Neves KR; Graciolli FG; dos Reis LM; Pasqualucci CA; Moysés RM; Jorgetti V
Kidney Int; 2004 Dec; 66(6):2237-44. PubMed ID: 15569312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
